Senior Scientist
Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai
Dr. Selma Bekri is an immunologist specialized in immunophenotyping and vaccine development for cancer and infectious diseases. As a Senior Scientist at the Tisch Cancer Institute, Mount Sinai in New York, she leads collaborative translational research projects in Multiple Myeloma. Her research focuses on understanding the immune system's response to immunotherapies and identifying biomarkers in myeloma patients undergoing immunotherapies using high-dimensional multi-omics data analysis.
Originally from Morocco and educated in France, Dr. Selma Bekri earned her Ph.D. in Immunology from the University of Nice Cote D’Azur, France, in 2014. During her postdoctoral training at the Tisch Cancer Institute at Mount Sinai, she conducted a preclinical study on a personalized neoantigen vaccine for Multiple Myeloma. Dr. Bekri was selected to join the 2023 SITC Women in Cancer Immunotherapy Network (WIN) conference and has presented her research at prestigious conferences, including the American Society of Hematology (ASH) Annual Meetings, the Keystone Symposium on Cancer Vaccines, and the International Myeloma Workshop, demonstrating her commitment to advancing the field of immunology and improving outcomes for Myeloma and cancer patients overall.